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Background
We have recently shown that the G protein-coupled recep-
tor 55 (GPR55) mediates intracellular effects of cannabi-
noids and other, non-cannabinoid ligands in addition to
the classical cannabinoid 1 (CB1) and 2 (CB2) receptors.
Here we show different signaling pathways triggered by
GPR55 in response to a panel of its agonists. In addition
the cytoskeleton rearrangement mediated by GPR55 is
investigated.
Methods
HEK-293 cells stably expressing the GPR55 receptor were
characterized in terms of signaling properties. To this end,
FLEX calcium release, reporter gene, dynamic mass redis-
tribution (DMR) and phalloidin actin staining assays have
been performed.
Results
Here we show that GPR55 is activated by lysophosphati-
dylinositol (LPI), AM251, SR141716A (rimonabant) and
AM281. GPR55 activation induces intracellular calcium
release, NF-κB, NFAT and CREB activation. Stimulation of
GPR55 induces F-actin formation under the control of
Gα13, RhoA and ROCK. We also show the suitability of
Corning® Epic® DMR assay for GPR55 ligand screening.
Conclusion
GPR55 as the novel cannabinoid receptor triggers distinct
signaling pathways in response to LPI and some classical
CB1 receptor antagonists. Stress fiber formation mediated
by GPR55 might show the function of this receptor in vivo.
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